Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and...
May 27 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, announced
today that it filed a patent application with the U.S. Patent
& Trademark Office (USPTO) concerning a method of inhibiting,
preventing, or treating neurological injuries due to viral,
bacterial, fungal, protozoan, or parasitic infections in humans and
in animals via administration of ANVS401 or related compounds.
“Researchers have noted the similarities between
many types of infections of the brain, including infections
resulting from COVID-19,” commented Maria Maccecchini, Ph.D., CEO
of Annovis Bio. “In fact, autopsies conducted in China have shown
the coronavirus to be present in the brain and some people infected
with the virus have developed encephalitis and other neurological
problems. In addition to our own studies, a number of universities
and companies are looking at how viral and bacterial infections
(e.g., herpes, HIV, Zika, Lyme disease, gingivitis) cause
neurological disorders and neurodegeneration. These short- and
long-term neurological problems are caused
because invasion of the brain by a virus or bacterium causes
levels of neurotoxic proteins to rise, which consequently impairs
axonal transport, induces inflammation, and leads to nerve cell
death. Because ANVS401 has been shown to protect nerve cells
against the ill effects of an increase of neurotoxic proteins in
the brain, we believe our compound could help with the treatment of
neurological diseases associated with COVID-19 and other
infections.”
A brain infection is a bacterial, viral, fungal,
protozoan, or parasitic infection of the tissue of the brain itself
or the membranes surrounding the brain and spinal cord.
Bacteria and viruses are the most common causes of brain
infections.
About Annovis Bio
Headquartered in Berwyn, Pennsylvania, Annovis
Bio, Inc. (Annovis) is a clinical-stage, drug platform company
addressing neurodegeneration, such as Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS).
We believe that we are the only company developing a drug for AD,
PD and AD-DS that inhibits more than one neurotoxic protein and,
thereby, improves the information highway of the nerve cell, known
as axonal transport. When this information flow is impaired, the
nerve cell gets sick and dies. We expect our treatment to improve
memory loss and dementia associated with AD and AD-DS, as well as
body and brain function in PD. We have an ongoing Phase 2a study in
AD patients and plan to commence a second Phase 2a study in PD
patients and AD patients. For more information on Annovis, please
visit the company’s website: www.annovisbio.com.
Forward-Looking Statements
Statements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. Such risks include
the possibility that the patent application referenced in this
release may not be approved, the timing of any decision by the
USPTO, and that ANVS401 is subject to further clinical trials and
may not be an effective treatment of infections. These and other
risks and uncertainties are described more fully in the section
titled “Risk Factors” in the Annual Report on Form 10-K for the
year ended December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:
Dave Gentry, CEO RedChip Companies Inc. 407-491-4498
Dave@redchip.com
SOURCE: Annovis Bio Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Apr 2023 to Apr 2024